Sulthiame

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Sulthiame

Examples of brand names: Ospolot [DE]

ATC code: N03AX03

Main use (for orientation): Epilepsy

Documented research summary

No reliable direct sulthiame–cannabinoid finding identified. The limited data are explicitly identified as a research gap, not as evidence of safety.

Uncertainties and limitations

No evidence of safety can be inferred from a lack of search results; the less-studied cannabinoids among the 28 in scope remain data-poor.

Consider differences in product, dose and route of administration, as well as individual organ function.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Evidence gap

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Sulthiame: carbonic anhydrase inhibition; product information mentions CYP2C19 effects.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Ospolot [UK]; Rolandic epilepsy; N03AX03 carbonic anhydrase inhibitor; additive acidosis risks with other carbonic anhydrase inhibitors; CNS symptoms possible. No prodrug identity stated in the text.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [C_LABEL_D0059]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: Ospolot 20 mg/ml Oral suspension, SmPC [C_LABEL_D0059]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[C_LABEL_D0059] Ospolot 20 mg/ml Oral suspension, SmPC

Original source / bibliographic reference

Authors: Pharmaceutical company not separately entered in the source field; product / official product information identified by title and URL

Year: 2026

Source type: Product information / SmPC

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility